Illumina (ILMN) Gets a Sell from Barclays
In a report released today, Luke Sergott from Barclays maintained a Sell rating on Illumina, with a price target of $110.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sergott covers the Healthcare sector, focusing on stocks such as Mettler-Toledo, Quest Diagnostics, and Twist Bioscience. According to TipRanks, Sergott has an average return of -0.2% and a 45.58% success rate on recommended stocks.
Illumina has an analyst consensus of Hold, with a price target consensus of $131.86.
Based on Illumina’s latest earnings release for the quarter ending September 28, the company reported a quarterly revenue of $1.08 billion and a net profit of $150 million. In comparison, last year the company earned a revenue of $1.08 billion and had a net profit of $705 million
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ILMN in relation to earlier this year. Most recently, in December 2025, Scott M Davies, the CLO of ILMN sold 323.00 shares for a total of $43,957.07.
Read More on ILMN:
